论文信息 - Comparison between the CLL‐IPI and the Barcelona‐Brno prognostic model: Analysis of 1299 newly diagnosed cases - 字舞流文

Comparison between the CLL‐IPI and the Barcelona‐Brno prognostic model: Analysis of 1299 newly diagnosed cases

T. Shanafelt | R. Foà | S. Molica | D. Rossi | G. Gaidano | A. Neri | M. Ferrarini | G. Cutrona | G. Tripepi | F. Morabito | M. Gentile | E. Vigna | A. Recchia | S. Bossio | I. Vincelli | L. Laurenti | F. Mauro | S. Parikh | I. Innocenti | R. Pasquale | S. Pepe | G. Uccello | K. G. Chaffee

[1] S. Malek,et al. Chronic Lymphocytic Leukemia , 2019, Methods in Molecular Biology.

[2] E. Montserrat,et al. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL‐IPI , 2017, American journal of hematology.

[3] J. Gribben,et al. Chronic lymphocytic leukaemia , 2017, Nature Reviews Disease Primers.

[4] F. Angrilli,et al. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients , 2016, American journal of hematology.

[5] T. Shanafelt,et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. , 2016, Blood.

[6] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.